Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma
Antineoplastic Combined Chemotherapy Protocols
R-CBorP is a safe and effective regimen in patients with relapsed/refractory indolent and MCLs. Most toxicities were grade 1 or 2, and a promising response rate was seen in this phase I study.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency